Emmaus Needs US FDA Advisory Cmte. To Rescue Sickle Cell Disease Candidate

FDA reviewers disagree with Emmaus' extrapolation methods for holes in efficacy data for its L-glutamine ahead of May 24 Oncologic Drugs Advisory Committee meeting.